Clinical trial
BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for…
NCT00185211 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00185211 |
|---|---|
| Title | BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study |
| Official title | Open-label, Multi-center Phase III Extension of the Double-blind, Placebo-controlled BENEFIT Study (no. 92012/304747) to Obtain Long-term Follow-up Data of Patients With Clinically Definite Multiple Sclerosis (MS) and Patients With a First Demyelinating Event Suggestive of MS Treated With 8 MIU (250… |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | Interferon beta-1b (Betaseron, BAY86-5046) |
| Enrollment | 468 |
| Start date | Aug 1, 2002 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2008 |
| First posted | Sep 16, 2005 |
| Last update posted | Dec 30, 2013 |
| Countries | Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Germany, Hungary, Israel, Italy, Netherlands and 8 more |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: